Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma
ConditionMelasma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorCosmetique Active International
About this trial
This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.
Eligibility criteria
Qualifiers
18-65 years
Phototype II-V
50% with sensitive skin (declarative);
Subjects should be affected by well defined symmetrical (on both sides of the face) epidermal melasma (clinically diagnosed under Wood's light examination) lasting since more than a year
Disqualifiers
Subjects under topical or systemic retinoids;
Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion;
Subjects under systemic immunosuppressants and considered immune compromised
Subjects under active treatment of melasma (including topicals or procedures) within the last 3 months
Trial design
Treatments tested in this trial
- Liftactiv® B3 Serum
- Liftactiv® B3 retinol night cream
- Sunscreen UVAage® Inter SPF 50+
- Mineral 89 cream
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov